Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this open-label phase Ib trial is to determine the maximum tolerated
dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in
patients with metastatic colorectal cancer. The secondary objectives are to describe the
safety and tolerablility, and to describe the clinical activity of PF-03446962 plus
regorafenib in terms of response rate and progression free survival